Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: A phase 3, randomised, observer-masked, placebo-controlled trial

The Lancet

Volumn 384, Issue 9951, 2014, Pages 1358-1365

  Capeding, Maria Rosario ^a   Tran, Ngoc Huu ^b   Hadinegoro, Sri Rezeki S ^c   Ismail, Hussain Imam Hj Muhammad ^d   Chotpitayasunondh, Tawee ^e   Chua, Mary Noreen ^f   Luong, Chan Quang ^b   Rusmil, Kusnandi ^g   Wirawan, Dewa Nyoman ^h   Nallusamy, Revathy ⁱ   Pitisuttithum, Punnee ^j   Thisyakorn, Usa ^j   Yoon, In Kyu ^k   Van Der Vliet, Diane ^l   Langevin, Edith ^l   Laot, Thelma ^l,m   Hutagalung, Yanee ^l,n   Frago, Carina ^l,n   Boaz, Mark ^a,h   Wartel, T Anh ^l,n   Tornieporth, Nadia G ^l   Saville, Melanie ^a,i   Bouckenooghe, Alain ^l   more..

^a RESEARCH INSTITUTE FOR TROPICAL MEDICINE   (Philippines)

^b PASTEUR INSTITUTE   (Viet Nam)

^c CIPTO MANGUNKUSUMO HOSPITAL   (Indonesia)

^d HOSPITAL KUALA LUMPUR   (Malaysia)

^e QUEEN SIRIKIT NATIONAL INSTITUTE OF CHILD HEALTH   (Thailand)

^f Cebu City Guadalupe Health Center Annex   (Philippines)

^g PADJADJARAN UNIVERSITY   (Indonesia)

^h UDAYANA UNIVERSITY   (Indonesia)

ⁱ Pantai Medical Centre   (Malaysia)

^j MAHIDOL UNIVERSITY   (Thailand)

^k ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^l SANOFI PASTEUR   (France)

^m Sanofi Pasteur   (Philippines)

ⁿ Sanofi Pasteur   (Singapore)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; RECOMBINANT VACCINE; TETRAVALENT DENGUE VACCINE; UNCLASSIFIED DRUG;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ARTICLE; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; DENGUE; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOGENICITY; INDONESIA; INFECTION; INFORMATION SYSTEM; INJECTION SITE REACTION; INTENTION TO TREAT ANALYSIS; INTERACTIVE VOICE RESPONSE SYSTEM; MALAYSIA; MALE; MASS COMMUNICATION; MULTICENTER STUDY; NORMAL HUMAN; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PHILIPPINES; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEROTYPE; THAILAND; VACCINATION; VIET NAM; WEB RESPONSE SYSTEM; ADOLESCENT; CLINICAL TRIAL; KAPLAN MEIER METHOD; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DENGUE; DENGUE VACCINES; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; KAPLAN-MEIER ESTIMATE; MALE; TREATMENT OUTCOME;

EID: 84908160975     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61060-6     Document Type: Article

References (20)

1. A Sabchareon, D Wallace, C Sirivichayakul et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial Lancet 380 2012 1559 1567
2. R Bhatia, A Dash, T Sunyoto Changing epidemiology of dengue in South-East Asia WHO-SEAJPH 2 2013 23 27
3. WHO Dengue: guidelines for diagnosis, treatment, prevention and control. New edition http://www.who.int/tdr/publications/documents/dengue-diagnosis.pdf 2009 (accessed June 7, 2014).
4. JP Messina, OJ Brady, TW Scott et al. Global spread of dengue virus types: mapping the 70 year history Trends Microbiol 22 2014 138 146
5. I Rodríguez-Barraquer, R Buathong, S Iamsirithaworn et al. Revisiting Rayong: shifting seroprofiles of dengue in Thailand and their implications for transmission and control Am J Epidemiol 179 2014 353 360
6. GH Dayan, M Thakur, M Boaz, C Johnson Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA Vaccine 31 2013 5047 5054
7. AS Hss, MT Koh, KK Tan et al. Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, phase III study Vaccine 31 2013 5814 5821
8. YS Leo, A Wilder-Smith, S Archuleta et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: phase II randomized controlled trial in Singapore Hum Vaccin Immunother 8 2012 1259 1271
9. CF Lanata, T Andrade, AI Gil et al. Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru Vaccine 30 2012 5935 5941
10. NH Tran, CQ Luong, TQH Vu et al. Safety and immunogenicity of recombinant, live attenuated tetravalent dengue vaccine (CYD-TDV) in healthy Vietnamese adults and children J Vaccines Vaccin 3 2012 1 7
11. WHO Dengue haemorrhagic fever: diagnosis, treatment, prevention and control. 2nd edn http://www.who.int/csr/resources/publications/dengue/Denguepublication/en/ 1997 (accessed June 7, 2014).
12. B Guy, B Barrere, C Malinowski, M Saville, R Teyssou, J Lang From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine Vaccine 29 2011 7229 7241
13. GH Dayan, P Garbes, F Noriega et al. Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil Am J Trop Med Hyg 89 2013 1058 1065
14. TM Timiryasova, MI Bonaparte, P Luo, R Zedar, BT Hu, SW Hildreth Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development Am J Trop Med Hyg 88 2013 962 970
15. J Hombach Guidelines for clinical trials of dengue vaccine in endemic areas J Clin Virol 46 suppl 2 2009 S7 S9
16. NE Breslow, NE Day Statistical methods in cancer research. Volume II - the design and analysis of cohort studies 1987 International Agency for Resarch on Cancer Lyon, France
17. DS Shepard, EA Undurraga, YA Halasa Economic and disease burden of dengue in Southeast Asia PLoS Negl Trop Dis 7 2013 e2055
18. JJ Sejvar, KS Kohl, R Bilynsky et al. Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data Vaccine 25 2007 5771 5792
19. W Huynh, DJ Cordato, E Kehdi, LT Masters, C Dedousis Post-vaccination encephalomyelitis: literature review and illustrative case J Clin Neurosci 15 2008 1315 1322
20. WHO Global strategy for dengue prevention and control 2012-2020 http://reliefweb.int/sites/reliefweb.int/files/resources/9789241504034-eng.pdf 2012 (accessed June 7, 2014).